This company is no longer active
ABIO Stock Overview
A clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ARCA biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.50 |
| 52 Week High | US$4.49 |
| 52 Week Low | US$1.56 |
| Beta | 0.89 |
| 1 Month Change | -16.67% |
| 3 Month Change | -32.43% |
| 1 Year Change | 21.95% |
| 3 Year Change | -19.87% |
| 5 Year Change | -52.11% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth
Apr 04
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Sep 24ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play
May 03Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Mar 18Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Nov 27Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
Jul 15Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
Mar 30Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19
Dec 15We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth
Dec 15
ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment
Nov 24ARCA biopharma reports Q3 results
Nov 02Shareholder Returns
| ABIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -36.2% | -3.3% | -0.4% |
| 1Y | 22.0% | -2.7% | 24.8% |
Return vs Industry: ABIO exceeded the US Biotechs industry which returned 13.7% over the past year.
Return vs Market: ABIO matched the US Market which returned 21.5% over the past year.
Price Volatility
| ABIO volatility | |
|---|---|
| ABIO Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABIO's share price has been volatile over the past 3 months.
Volatility Over Time: ABIO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 3 | Tom Keuer | www.arcabio.com |
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19.
ARCA biopharma, Inc. Fundamentals Summary
| ABIO fundamental statistics | |
|---|---|
| Market cap | US$50.63m |
| Earnings (TTM) | -US$7.20m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.0x
P/E RatioIs ABIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABIO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.20m |
| Earnings | -US$7.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ABIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/29 22:39 |
| End of Day Share Price | 2024/08/29 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ARCA biopharma, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Robert Wasserman | Dawson James Securities |
| Jason Napodano | Zacks Investment Research Inc. |